Neurosense Therapeutics Ltd

Change company Symbol lookup

Select an option...

NRSN Neurosense Therapeutics Ltd

ST Sensata Technologies Holding PLC

ZTS Zoetis Inc

AZZ AZZ Inc

CRM Salesforce Inc

IVR-C Invesco Mortgage Capital Inc

MSM MSC Industrial Direct Co Inc

BLUE bluebird bio Inc

ENSV Enservco Corp

ULIHF United Laboratories International Holdings Ltd

Go

-- Biomarkers show the potential of NeuroSense's combination drug CogniC to treat Alzheimer's disease -- CogniC is expected to advance into clinical trials in 2023 NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing...(PR Newswire)

FinancialNewsMedia.com News Commentary Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent treatment. Factors such as the increasing prevalence and incidence of pancreatic...(PR Newswire)

InvestorsObserver issues critical PriceWatch Alerts for NRSN, BOXD, SNAP, REAL, and AXDX. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

-- Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in...(PR Newswire)

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the Company will participate in Maxim Group's panel discussion on Innovations in ALS: Exploring New...(PR Newswire)

-- Phase IIa study successfully met safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biomarkers -- PrimeC has Orphan Drug Designation with the FDA and EMA (PR Newswire)

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today reported its financial results for the quarter ended March 31, 2022 and provided a business update. (PR Newswire)

-- Ferenc Tracik, MD to deliver presentation - "From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS" -- Phase IIb ALS study for NeuroSense's combination therapy PrimeC expected to commence Q2 2022 (PR Newswire)